|
DLA Piper LLP
(US)
401
Congress Avenue, Suite 2500
Austin,
Texas 78701-3799
www.dlapiper.com
T 512.457.7000
F 512.457.7001
|
March
1, 2018
GT Biopharma, Inc.
1825 K
Street NW, Suite 510
Washington,
DC 20006
Re: Registration Statement on Form S-3
Ladies
and Gentlemen:
We have acted as counsel to GT Biopharma, Inc., a Delaware
corporation (the “Company”)
in connection with the preparation and filing of a registration
statement on Form S-3 (the “Registration
Statement”) relating to
the registration under the Securities Act of 1933, as amended (the
“Act”),
of up to an aggregate of 3,388,884 shares (the
“Shares”)
of the Company’s common stock, par value $0.001 per share
(the “Common
Stock”), plus an
indeterminate number of shares of Common Stock that may be issued
upon stock splits, stock dividends or similar transactions in
accordance with Rule 416 of the Act, which may be offered and sold
from time to time by the selling stockholders named in the
Registration Statement. The Shares consist of (i) 1,694,442 shares
of Common Stock that may be acquired upon exercise of outstanding
warrants (“Warrants”)
and (ii) 1,694,442 shares of Common Stock issuable upon conversion
of the senior convertible notes (the “Notes”).
As the basis for the opinions hereinafter expressed, we have
examined: (i) originals, or copies certified or otherwise
identified, of (a) the Registration Statement; (b) the
Certificate of Incorporation of the Company, as amended to date;
(c) the Bylaws of the Company; (d) certain resolutions of
the Board of Directors of the Company; and (e) such other
instruments and documents as we have deemed necessary or advisable
for the purposes of this opinion; and (ii) such statutes,
including the Delaware General Corporation Law, and regulations as
we have deemed necessary or advisable for the purposes of this
opinion. In such examination, we have assumed the genuineness of
all signatures and the authenticity of all documents submitted to
us as originals and the conformity to the originals of all
documents submitted to us as copies.
Based on such examination, we are of the opinion
that the Shares are, or will be, when and to the
extent issued upon conversion of the Notes or exercise of the
Warrants in accordance with the terms thereof, will be validly
issued, fully paid and nonassessable.
We express no opinion other than as to the federal laws of the
United States of America and the Delaware General Corporation Law
(including the statutory provisions, the applicable provisions of
the Delaware Constitution and reported judicial decisions
interpreting the foregoing). We express no opinion as to any matter
other than as expressly set forth above, and no opinion, other than
the opinion given herein, may be inferred or implied
herefrom.
We consent to the use of this opinion as an exhibit to the
Registration Statement, and we consent to the reference of our name
under the caption “Legal Matters” in the prospectus
forming part of the Registration Statement. In giving our consent,
we do not thereby admit that we are within the category of persons
whose consent is required under Section 7 of the Act or the
rules and regulations promulgated thereunder.
Very
truly yours,
|
/s/ DLA
Piper LLP (US)
|
DLA
Piper LLP (US)
|